OncoImmune is a privately held, clinical-stage biopharmaceutical company based in Rockville, Maryland focused on discovering and developing novel immunotherapies for cancer, inflammation and autoimmune diseases. Its lead product, CD24Fc, is a first-in-class biologic that modulates host inflammatory responses and is being evaluated across indications. The company has two Phase III programs: one testing CD24Fc in severe and critical COVID-19 patients and another in leukemia patients at risk for acute graft‑versus‑host disease after allogeneic hematopoietic stem cell transplant. The COVID-19 Phase III trial is active at 17 medical centers, plans to enroll over 270 patients, and is near its enrollment target with topline readouts expected soon. OncoImmune reported positive Phase IIa results for CD24Fc in prophylaxis of acute GvHD, showing improvement in 180‑day Grade III–IV aGvHD‑free survival and other clinical endpoints. The company plans to use the proceeds from the financing to support its late‑stage clinical programs and expand its product pipeline. OncoImmune is a privately-held, clinical-stage biopharmaceutical company focused on discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases. The company’s lead clinical product, CD24Fc, is in a Phase II trial for prevention of acute graft‑versus‑host disease (GvHD) following myeloablative allogeneic hematopoietic stem cell transplant and has orphan drug designation for GvHD in the US and Europe. New capital will be used primarily to develop a novel clinical-stage asset targeting the CD24‑Siglec pathway that regulates host inflammatory responses and has implications across autoimmune disease, cancer and GvHD. Funding will also support development of other immuno‑oncology assets, with a focus on solid‑tumor‑targeting monoclonal antibodies, cancer vaccines, and management of immunotherapy‑related adverse events. OncoImmune entered into a license and option agreement with Pfizer in 2016 for ONC‑392, a preclinical IO program. The company is based in Rockville, Maryland.

Total raised

$71M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2020